tiprankstipranks
Biofrontera’s Ameluz Gel FDA Approval for Higher Dosage
Company Announcements

Biofrontera’s Ameluz Gel FDA Approval for Higher Dosage

Pick the best stocks and maximize your portfolio:

Biofrontera ( (BFRI) ) just unveiled an update.

Biofrontera Inc. announced FDA approval for increasing the maximum dosage of its Ameluz® gel from one to three tubes per treatment, offering enhanced flexibility for dermatologists treating actinic keratosis on the face and scalp. This expanded use is supported by clinical studies confirming the safety and efficacy of the higher dosage. The company is now working towards securing reimbursement for the updated dosage, signaling a significant advancement in photodynamic therapy options for patients.

For a thorough assessment of BFRI stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskBiofrontera Secures $4.2M for Strategic Growth Initiatives
TipRanks Auto-Generated NewsdeskBiofrontera Inc. Reports Q3 2024 Earnings Growth
Brian AndersonBFRI Earnings this Week: How Will it Perform?
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App